Research Topics
| JAMES WILLIAM YOUNGSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Dendritic cells: expansion and differentiation with hematopoietic growth factorsJ W Young
Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10021 6094, USA
Curr Opin Hematol 6:135-44. 1999..This has rendered dendritic cells accessible to detailed experimental evaluations and clinical applications. Dendritic cells provide a powerful means of controlling both normal and pathologic immunity...- Dendritic cells in transplantation and immune-based therapiesJames W Young
Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
Biol Blood Marrow Transplant 13:23-32. 2007..The use of defined DC subtypes to stimulate both innate and adaptive immunity, either in combination or in a prime-boost vaccine sequence, may prove most useful clinically by harnessing both effector cell compartments... 
Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functionsAdam M Boruchov
Laboratory of Cellular Immunobiology, Hematology Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Clin Invest 115:2914-23. 2005..The data also suggest novel strategies for targeting antigens to the activating or inhibitory FcgammaRs on human DCs to generate either antigen-specific immunity or tolerance...- Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplantsDana Jaffe
Department of Pediatrics, Bone Marrow Transplant Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Blood 108:2470-5. 2006.... - Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignanciesTrudy N Small
Department of Pediatrics, Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Biol Blood Marrow Transplant 13:235-44. 2007..For 18 patients with MDS (< or = RAEB-2) or high-risk myeloproliferative disorder, the estimated 3 year DFS is 61%. These data demonstrate the curative potential of this regimen in patients with high-risk myeloid malignancies... - Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplantDavid M Weinstock
Adult Allogeneic Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Biol Blood Marrow Transplant 13:615-21. 2007..The high mortality of VRE in the early posttransplant period supports the use of empiric antibiotics with activity against VRE during periods of fever and neutropenia in colonized patients... - T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulinAnn A Jakubowski
Adult Allogeneic Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10065, USA
Blood 110:4552-9. 2007..Life-threatening OIs occurred in 3 of 52 patients and was fatal in 1. This study demonstrates durable engraftment with a low incidence of GvHD despite the lack of ATG, as well as the curative potential of this regimen... - Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failureJoseph H Chewning
Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Biol Blood Marrow Transplant 13:1313-23. 2007.... 
Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblingsHugo Castro-Malaspina
The Allogeneic Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Biol Blood Marrow Transplant 14:458-68. 2008....- Dendritic cells have the option to express IDO-mediated suppression or notDavid H Munn
Blood 105:2618. 2005 - Langerhans cells derived from genetically modified human CD34+ hemopoietic progenitors are more potent than peptide-pulsed Langerhans cells for inducing antigen-specific CD8+ cytolytic T lymphocyte responsesJianda Yuan
Laboratory of Cellular Immunobiology, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
J Immunol 174:758-66. 2005..LCs genetically modified to express fluMP are also more potent stimulators of Ag-specific CD8(+) T cell responses than are peptide-pulsed LCs... - Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantationsSharon R Lewin
Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY
Blood 100:2235-42. 2002..T-cell neogenesis, appropriate to age but delayed in adult recipients of T-cell-depleted allografts, justifies interventions to hasten this process and to stimulate desirable cellular immune responses... - Expression of a functional eotaxin (CC chemokine ligand 11) receptor CCR3 by human dendritic cellsSylvie Beaulieu
Laboratory of Cellular Physiology and Immunology, The Rockefeller University and Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College, Cornell University, New York, NY 10021, USA
J Immunol 169:2925-36. 2002..We postulate that expression of CCR3 may underlie situations where both DCs and eosinophils accumulate in vivo, such as the lesions of patients with Langerhans cell granulomatosis... - Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantationGudrun Ratzinger
Laboratory of Cellular Immunobiology, Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA
Blood 101:1422-9. 2003..Whether these results support a separation of deleterious from beneficial graft-host interactions at the level of antigen presentation, rather than solely at the level of T cells, will require further evaluation... - Erythromelalgia precipitated by acral erythema in the setting of thrombocytopeniaLisa M Coppa
Department of Dermatology, New York-Presbyterian Hospital, Weill Cornell Center, New York, New York, USA
J Am Acad Dermatol 48:973-5. 2003.... - Infection of mature monocyte-derived dendritic cells with human cytomegalovirus inhibits stimulation of T-cell proliferation via the release of soluble CD83Brigitte Senechal
Laboratory of Cellular Immunobiology, Allogenic Transplantation and Clinical Immunology Services, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021 6094, USA
Blood 103:4207-15. 2004..We have thus discovered a new mechanism by which HCMV infection may establish a nonlytic reservoir in mature moDCs that inhibits DC-mediated T-cell responses... - Mature human Langerhans cells derived from CD34+ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocGudrun Ratzinger
Laboratory of Cellular Immunobiology, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
J Immunol 173:2780-91. 2004..These findings merit further comparisons in clinical trials designed to determine the physiologic relevance of these distinctions in activity between LCs and other DCs... - Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cellsCHRISTIAN MUNZ
Laboratory of Viral Immunobiology, The Rockefeller University, New York, NY 10021 6399, USA
Blood 105:266-73. 2005..Hence, the principal myeloid DCs differ in critical ways regarding the stimulation of NK and T lymphocytes and could be used or targeted accordingly in DC-based immunotherapies... - Sirolimus (rapamycin) induced proteinuria in a patient undergoing allogeneic hematopoietic stem cell transplantKenar D Jhaveri
Transplantation 86:180-1. 2008 - Predominant autoantibody production by early human B cell precursorsHedda Wardemann
Laboratory of Molecular Immunology, Rockefeller University, New York, NY 10021, USA
Science 301:1374-7. 2003..Most of these autoantibodies were removed from the population at two discrete checkpoints during B cell development. Inefficient checkpoint regulation would lead to substantial increases in circulating autoantibodies... - Scalable expansion of potent genetically modified human langerhans cells in a closed system for clinical applicationsJianda Yuan
Laboratory of Cellular Immunobiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Immunother 30:634-43. 2007..We have thus developed a scalable closed process to expand genetically modified, biologically functional CD34+ hematopoietic progenitor cell-derived LCs for phase I clinical trials... - Langerhans-type dendritic cells genetically modified to express full-length antigen optimally stimulate CTLs in a CD4-dependent mannerJianda Yuan
Laboratory of Cellular Immunobiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
J Immunol 176:2357-65. 2006..LCs, transduced with a retroviral vector encoding full-length Ag, stimulate potent CTLs directed against multiple epitopes in a CD4(+) Th cell-dependent manner... - CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapyPing Zhou
Sloan Kettering Institute, Department of Medicine, New York, NY 10021, USA
Blood 111:3403-6. 2008..These data provide a rationale for the novel therapeutic targeting of CD32B using the humanized 2B6 MoAb in patients with systemic AL-amyloidosis... - Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunityMarco Rossi
Laboratory of Cellular Immunobiology, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
J Immunol 175:1373-81. 2005..This review will address these developments in an attempt to integrate the activities of different DCs in coordinating innate and adaptive immunity...
Research Grants
- GENETIC MODIFICATION OF HUMAN DENDRITIC CELLS FOR CANCER IMMUNITYJAMES WILLIAM YOUNG; Fiscal Year: 2010..These approaches should find their greatest application in treating minimal residual disease after primary therapy.) ..
- TUMOR IMMUNITY GENERATED BY DENDRITIC CELLSJames Young; Fiscal Year: 2009..New and improved approaches for the immune-based treatment of cancer are anticipated, with the most effective application likely being the treatment of minimal residual disease after primary therapy.) ..
- GENETIC MODIFICATION OF HUMAN DENDRITIC CELLS FOR CANCER IMMUNITYJames Young; Fiscal Year: 2007..These approaches should find their greatest application in treating minimal residual disease after primary therapy.) ..
- Immune responses to gene-modified, autologous dendritic cell vaccines in melanomaJames Young; Fiscal Year: 2007..LAY SUMMARY: Genetic alterations of specialized Langerhans-type dendritic cells will be tested for safety, toxicity, and the stimulation of tumor- specific immunity in patients with advanced stage III-IV melanoma.) ..
- TUMOR IMMUNITY GENERATED BY DENDRITIC CELLSJames Young; Fiscal Year: 2007..New and improved approaches for the immune-based treatment of cancer are anticipated, with the most effective application likely being the treatment of minimal residual disease after primary therapy.) ..
- Alemtuzumab treatment of steroid-refractory acute GvHDJames Young; Fiscal Year: 2004..abstract_text> ..
- TUMOR IMMUNITY GENERATED BY DENDRITIC CELLSJAMES WILLIAM YOUNG; Fiscal Year: 2010..New and improved approaches for the immune-based treatment of cancer are anticipated, with the most effective application likely being the treatment of minimal residual disease after primary therapy.) ..